Trial Profile
An Open-label Study of MabThera on Objective Overall Tumor Response in Treatment-naive Patients With Non-bulky Follicular Non-Hodgkin's Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 May 2013
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Biomarker; Therapeutic Use
- Sponsors Roche
- 14 Jul 2011 New trial record